Legis Daily

A bill to increase reporting transparency and accountability with respect to Food and Drug Administration user fees.

USA115th CongressS-1062| Senate 
| Updated: 5/4/2017
Richard Burr

Richard Burr

Republican Senator

North Carolina

Cosponsors (1)
Todd Young (Republican)

Health, Education, Labor, and Pensions Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
FDA Reporting Transparency and Accountability Act This bill expands reporting requirements related to the performance of the Food and Drug Administration (FDA), including to require additional information on timeliness and personnel and publication every 30 days of information regarding FDA guidance and meetings.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 4, 2017
Introduced in Senate
May 4, 2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • May 4, 2017
    Introduced in Senate


  • May 4, 2017
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Health

Related Bills

  • HR 115-2430: FDA Reauthorization Act of 2017
  • S 115-934: FDA Reauthorization Act of 2017
Computers and information technologyCongressional oversightDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Government buildings, facilities, and propertyGovernment employee pay, benefits, personnel managementGovernment information and archivesLicensing and registrationsPerformance measurementPrescription drugsPublic contracts and procurementPublic participation and lobbyingUser charges and fees

A bill to increase reporting transparency and accountability with respect to Food and Drug Administration user fees.

USA115th CongressS-1062| Senate 
| Updated: 5/4/2017
FDA Reporting Transparency and Accountability Act This bill expands reporting requirements related to the performance of the Food and Drug Administration (FDA), including to require additional information on timeliness and personnel and publication every 30 days of information regarding FDA guidance and meetings.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 4, 2017
Introduced in Senate
May 4, 2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • May 4, 2017
    Introduced in Senate


  • May 4, 2017
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Richard Burr

Richard Burr

Republican Senator

North Carolina

Cosponsors (1)
Todd Young (Republican)

Health, Education, Labor, and Pensions Committee

Health

Related Bills

  • HR 115-2430: FDA Reauthorization Act of 2017
  • S 115-934: FDA Reauthorization Act of 2017
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Computers and information technologyCongressional oversightDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Government buildings, facilities, and propertyGovernment employee pay, benefits, personnel managementGovernment information and archivesLicensing and registrationsPerformance measurementPrescription drugsPublic contracts and procurementPublic participation and lobbyingUser charges and fees